Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00903396 · ADVERSE EVENTS

Adverse events

Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer · Source last updated 2017-11-24

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Adverse events occurred during the study; they are not necessarily caused by treatment. Serious events are not interchangeable with severe/grade 3–4 events. These safety populations may differ from efficacy populations.

Collection time frame
Not reported
Other-event reporting threshold
0%

Not enough patients were accrued. In order to avoid identification of patients, no results will be entered.

Participants affected / participants at risk, as reported
Safety groupSerious eventsOther eventsDeaths
Arm I

Patients receive palonosetron hydrochloride IV on day 1. palonosetron hydrochloride: Given IV

0 / 00 / 0Not reported / Not reported
Arm II

Patients receive palonosetron hydrochloride IV on days 1 and 4. palonosetron hydrochloride: Given IV

0 / 00 / 0Not reported / Not reported
Arm III

Patients receive placebo IV on day 1. placebo: Given IV

0 / 00 / 0Not reported / Not reported
Arm IV

Patients receive placebo IV on days 1 and 4. placebo: Given IV

0 / 00 / 0Not reported / Not reported

Group identifiers: EG000: Arm I · EG001: Arm II · EG002: Arm III · EG003: Arm IV

Serious adverse events

Event terms and counts are source-reported; expand to read more. A reporting threshold may omit less frequent events.

    Other reported adverse events

    Event terms and counts are source-reported; expand to read more. A reporting threshold may omit less frequent events.

      Complete source fields
      description
      Not enough patients were accrued. In order to avoid identification of patients, no results will be entered.
      event Groups
      1. description
        Patients receive palonosetron hydrochloride IV on day 1. palonosetron hydrochloride: Given IV
        id
        EG000
        other Num Affected
        0
        other Num At Risk
        0
        serious Num Affected
        0
        serious Num At Risk
        0
        title
        Arm I
      2. description
        Patients receive palonosetron hydrochloride IV on days 1 and 4. palonosetron hydrochloride: Given IV
        id
        EG001
        other Num Affected
        0
        other Num At Risk
        0
        serious Num Affected
        0
        serious Num At Risk
        0
        title
        Arm II
      3. description
        Patients receive placebo IV on day 1. placebo: Given IV
        id
        EG002
        other Num Affected
        0
        other Num At Risk
        0
        serious Num Affected
        0
        serious Num At Risk
        0
        title
        Arm III
      4. description
        Patients receive placebo IV on days 1 and 4. placebo: Given IV
        id
        EG003
        other Num Affected
        0
        other Num At Risk
        0
        serious Num Affected
        0
        serious Num At Risk
        0
        title
        Arm IV
      frequency Threshold
      0

      Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

      Preserved source evidence · Not medical advice